Constructing New Product Development Portfolios with Internal and External Projects

References

• Adams J (1963) Toward an understanding of inequity. J. Abnormal Soc. Psych. 67(5):422–436.Crossref, Google Scholar
• Adner R (2007) Real options and resource reallocation processes. Reuer J, Tong T, eds. Real Options Theory (Advances in Strategic Management, Vol. 24) (Emerald Publishing, Bingley, UK), 363–372.Crossref, Google Scholar
• Ali A, Kalwani M, Kovenock D (1993) Selecting product development projects: Pioneering versus incremental innovation strategies. Management Sci. 39(3):255–274.Link, Google Scholar
• Antic N, Persico N (2020) Cheap talk with endogenous conflict of interest. Econometrica 88(6):2663–2695.Crossref, Google Scholar
• Arora A, Fosfuri A (2003) Licensing the market for technology. J. Econom. Behav. Organ. 52(2):277–295.Crossref, Google Scholar
• Arora A, Gambardella A (2010) The market for technology. Hall B, Rosenberg N, eds. Handbook of the Economics of Innovation (Elsevier, Amsterdam), 641–678.Crossref, Google Scholar
• Arora A, Belenzon S, Suh J (2022) Science and the market for technology. Management Sci. 68(10):7176–7201.Link, Google Scholar
• Aryal G, Ciliberto F, Farmer L, Khmelnitskaya E (2024) Valuing pharmaceutical drug innovations, Working paper, Washington University in St. Louis, St. Louis.Google Scholar
• Aumann R, Hart S (2003) Long cheap talk. Econometrica 71(6):1619–1660.Crossref, Google Scholar
• Balakrishnan R (1991) Information acquisition and resource allocation decisions. Accounting Rev. 60(1):120–139.Google Scholar
• Bentzien J, Bharadwaj R, Thompson D (2015) Crowdsourcing in pharma: A strategic framework. Drug Discovery Today 20(7):874–883.Crossref, Google Scholar
• Bhaskaran S, Krishnan V (2009) Effort, revenue, and cost sharing mechanisms for collaborative new product development. Management Sci. 55(7):1152–1169.Link, Google Scholar
• Bhaskaran S, Ramachandran K (2011) Managing technology selection and development risk in competitive environments. Production Oper. Management 20(4):541–555.Crossref, Google Scholar
• Bhattacharya S, Gaba V, Hasija S (2015) A comparison of milestone-based and buyout options contracts for coordinating R&D partnerships. Management Sci. 61(5):963–978.Link, Google Scholar
• Birkinshaw J (2001) Strategies for managing internal competition. California Management Rev. 44(1):21–38.Crossref, Google Scholar
• Blume A, Sobel J (1995) Communication-proof equilibria in cheap-talk games. J. Econom. Theory 65(2):359–382.Crossref, Google Scholar
• Bolton G, Ockenfels A (2000) ERC: A theory of equity, reciprocity, and competition. Amer. Econom. Rev. 90(1):166–193.Crossref, Google Scholar
• Bower J (1970) Managing the Resource Allocation Process (Harvard Business School Press, Cambridge, MA).Google Scholar
• Brown S, Goetzmann W, Liang B, Schwarz C (2012) Trust and delegation. J. Financial Econom. 103(2):221–234.Crossref, Google Scholar
• Caskey J, Nagar V, Petacchi P (2010) Reporting bias with an audit committee. Accounting Rev. 85(2):447–481.Crossref, Google Scholar
• Cassiman B, Veugelers R (2006) In search of complementarity in innovation strategy: Internal R&D and external knowledge acquisition. Management Sci. 52(1):68–82.Link, Google Scholar
• Chakraborty A, Harbaugh R (2010) Comparative cheap talk. Amer. Econom. Rev. 100(5):2361–2382.Crossref, Google Scholar
• Chao R, Kavadias S (2008) A theoretical framework for managing the new product development portfolio: When and how to use strategic buckets. Management Sci. 54(5):907–921.Link, Google Scholar
• Chao R, Kavadias S, Gaimon C (2009) Revenue driven resource allocation: Funding authority, incentives, and new product development portfolio management. Management Sci. 55(9):1556–1569.Link, Google Scholar
• Chao R, Lichtendahl K Jr, Grushka-Cockayne Y (2014) Incentives in a stage-gate-process. Production Oper. Management 23(8):1286–1298.Crossref, Google Scholar
• Chen Y, Kartik N, Sobel J (2008) Selecting cheap-talk equilibria. Econometrica 76(1):117–136.Crossref, Google Scholar
• Coff R (1999) How buyers cope with uncertainty when acquiring firms in knowledge-intensive industries: Caveat emptor. Organ. Sci. 10(2):144–161.Link, Google Scholar
• Cohen W, Levinthal D (1989) Innovation and learning: The two faces of R&D. Econom. J. 99(397):569–596.Google Scholar
• Cooper R, Edgett S, Kleinschmidt E (2000) New problems, new solutions: Making portfolio management more effective. Res. Tech. Management 43(2):18–33.Crossref, Google Scholar
• Cooper R, Edgett S, Kleinschmidt E (2001) Portfolio Management for New Products, 2nd ed. (Perseus Books, New York).Google Scholar
• Crama P, De Reyck B, Degraeve Z (2008) Milestone payments or royalties? Contract design for R&D licensing. Oper Res. 56(6):1539–1552.Link, Google Scholar
• Crama P, De Reyck B, Taneri N (2017) Licensing contracts: Control rights, options, and timing. Management Sci. 63(4):1131–1149.Link, Google Scholar
• Ding M, Eliashberg J (2002) Structuring the new product development pipeline. Management Sci. 48(3):343–363.Link, Google Scholar
• Ederer F, Manso G (2013) Is pay for performance detrimental to innovation? Management Sci. 59(7):1496–1513.Link, Google Scholar
• Friebel G, Raith M (2009) Resource allocation and organizational form. Amer. Econom. J. Microeconom. 2(2):1–33.Google Scholar
• Fudenberg D, Tirole J (1991) Game Theory (MIT Press, Cambridge, MA).Google Scholar
• Gao P, Fan X, Huang Y, Chen YJ (2022) Resource allocation among competing innovators. Management Sci. 68(8):6059–6074.Link, Google Scholar
• Gerardi D, Maestri L (2012) A principal-agent model of sequential testing. Theoretical Econom. 7(3):425–463.Crossref, Google Scholar
• Gershkov A, Perry M (2012) Dynamic contracts with moral hazard and adverse selection. Rev. Econom. Stud. 79(1):268–306.Crossref, Google Scholar
• Girotra K, Terwiesch C, Ulrich K (2007) Valuing R&D projects in a portfolio: Evidence from the pharmaceutical industry. Management Sci. 53(9):1452–1466.Link, Google Scholar
• Gomes R, Gottlieb D, Maestri L (2016) Experimentation and project selection: Screening and learning. Game Econom. Behav. 96:145–169.Crossref, Google Scholar
• Hagedoorn J, Wang N (2012) Is there complementarity or substitutability between internal and external R&D strategies? Nature Rev. Drug Discovery 41(6):1072–1083.Google Scholar
• Hasija S, Bhattacharya S (2017) Contracting for new product development. Ha A, Tang C, eds. Handbook of Information Exchange in Supply Chain Management (Springer, Cham, Switzerland), 123–144.Crossref, Google Scholar
• Hess A, Rothaermel F (2011) When are assets complementary? Star scientists, strategic alliances, and innovation in the pharmaceutical industry. Strategic Management J. 32(8):895–909.Crossref, Google Scholar
• Huckman R, Pisano G, Rennella M (2010) Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics (Harvard Business School Publishing, Boston).Google Scholar
• Hughes J, Rees S, Kalindjian S, Philpott K (2011) Principles of early drug discovery. British J. Pharmacology 162(6):1239–1249.Crossref, Google Scholar
• Hutchison-Krupat J (2018) Communication, incentives, and the execution of a strategic initiative. Management Sci. 64(7):3380–3399.Link, Google Scholar
• Hutchison-Krupat J, Kavadias S (2015) Strategic resource allocation: Top-down, bottom-up, and the value of strategic buckets. Management Sci. 61(2):391–412.Link, Google Scholar
• Hutchison-Krupat J, Kavadias S (2018) Organizational enablers for NPD portfolio selection. IEEE Trans. Engrg. Management 65(1):59–71.Crossref, Google Scholar
• Jeppesen L, Lakhani K (2010) Marginality and problem-solving effectiveness in broadcast search. Organ. Sci. 21(5):1016–1033.Link, Google Scholar
• Katz M, Shapiro C (1986) How to license intangible property. Quart. J. Econom. 101(3):567–589.Crossref, Google Scholar
• Kavadias S, Hutchison-Krupat J (2020) A framework for managing innovation. Druehl C, Elmaghraby W, eds. Pushing the Boundaries: Frontiers in Impactful OR/OM Research (INFORMS, Catonsville, MD), 202–228.Link, Google Scholar
• Khetan R (2020) Biopharma licensing and M&A trends in the 21st-century landscape. J Commerce Biotech. 25(3):37–51.Google Scholar
• Klingebiel R (2022) Motivating innovation: Tunnels vs. funnels. Strategy Sci. 7(4):300–316.Link, Google Scholar
• Klingebiel R, Rammer C (2014) Resource allocation strategy for innovation portfolio management. Strategic Management J. 35(2):246–268.Crossref, Google Scholar
• Krishnan V, Ulrich K (2001) Product development decisions: A review of the literature. Management Sci. 47(1):1–21.Link, Google Scholar
• Lambert R (1986) Executive effort and selection of risky projects. RAND J Econom. 17(1):77–88.Crossref, Google Scholar
• Landis M, Bhattachar S, Yazdanian M, Morrison J (2018) Why pharmaceutical scientists in early drug discovery are critical for influencing the design and selection of optimal drug candidates. AAPS PharmSciTech. 19(1):1–10.Crossref, Google Scholar
• Levitt S, Snyder C (1997) Is no news bad news? Information transmission and the role of “early warning” in the principal-agent model. RAND J Econom. 28(4):641–661.Crossref, Google Scholar
• Li Z, Rantakari H, Yang H (2016) Competitive cheap talk. Games Econom Behav. 96:65–89.Crossref, Google Scholar
• Loch C, Kavadias S (2008) Handbook of New Product Development Management (Routledge, London).Google Scholar
• Lombardino J, Lowe J III, (2004) The role of the medicinal chemist in drug discovery—Then and now. Nature Rev. Drug Discovery 3(10):853–862.Crossref, Google Scholar
• Manso G (2011) Motivating innovation. J Finance 66(5):1823–1860.Crossref, Google Scholar
• Markou P, Kavadias S, Oraiopoulos N (2023) Rival signals and project selection: Insights from the drug discovery process. Management Sci. 69(9):5298–5315.Link, Google Scholar
• Maskin E (2011) Commentary: Nash equilibrium and mechanism design. Games Econom. Behav. 71(1):9–11.Crossref, Google Scholar
• Moeller S, Brady C (2014) Intelligent M&A: Navigating the Mergers and Acquisitions Minefield, 2nd ed. (John Wiley & Sons, Chichester, UK).Google Scholar
• Oraiopoulos N, Kavadias S (2014) The path-dependent nature of R&D search: Implications for (and from) competition. Production Oper. Management 23(8):1450–1461.Crossref, Google Scholar
• Oraiopoulos N, Kavadias S (2020) Is diversity (un-)biased? Project selection decisions in executive committees. Manufacturing Service Oper. Management 22(5):906–924.Link, Google Scholar
• Petrova E (2014) Innovation in the pharmaceutical industry: The process of drug discovery and development. Ding M, Eliashberg J, Stremersch S, eds. Innovation and Marketing in the Pharmaceutical Industry (Springer, New York), 19–81.Crossref, Google Scholar
• Reuer J, Sakhartov A (2021) Economies of scope and optimal due diligence in corporate acquisitions. Organ. Sci. 32(4):1100–1119.Link, Google Scholar
• Ringel M, Choy M (2017) Do larger mergers increase or decrease the productivity of pharmaceutical R&D? Drug Discovery Today 22(12):1749–1753.Crossref, Google Scholar
• Santiago L, Oliveira Soares V (2018) Strategic alignment of an R&D portfolio by crafting the set of buckets. IEEE Trans. Engrg. Management 67(2):309–321.Crossref, Google Scholar
• Sapienza A, Lombardino J (2002) Recognizing, appreciating, and capturing the tacit knowledge of R&D scientists. Drug Development Res. 57(2):51–57.Crossref, Google Scholar
• Schilling M (2017) Strategic Management of Technological Innovation, 5th ed. (McGraw-Hill, New York).Google Scholar
• Schlapp J, Schumacher G (2022) Delegated concept testing in new product development. Oper. Res. 70(5):2732–2748.Link, Google Scholar
• Schlapp J, Oraiopoulos N, Mak V (2015) Resource allocation decisions under imperfect evaluation and organizational dynamics. Management Sci. 61(9):2139–2159.Link, Google Scholar
• Schuhmacher A, Germann PG, Trill H, Gassmann O (2013) Models for open innovation in the pharmaceutical industry. Drug Discovery Today 18(23–24):1133–1137.Crossref, Google Scholar
• Schuhmacher A, Gassmann O, Bieniok D, Hinder M, Hartl D (2022) Open innovation: A paradigm shift in pharma R&D. Drug Discovery Today 27(9):2395–2405.Crossref, Google Scholar
• Schuhmacher A, Hinder M, von Stegmann und Stein A, Hartl D, Gassmann O (2023) Analysis of pharma R&D productivity—A new perspective needed. Drug Discovery Today 28(10):103726.Crossref, Google Scholar
• Sengul M, Almeida Costa A, Gimeno J (2019) The allocation of capital within firms: A review and integration toward a research revival. Acad. Management Ann. 13(1):43–83.Crossref, Google Scholar
• Shane S, Ulrich K (2004) Technological innovation, product development, and entrepreneurship in Management Science. Management Sci. 50(2):133–144.Link, Google Scholar
• Sharpe P, Keelin T (1998) How SmithKline Beecham makes better resource-allocation decisions. Harvard Bus. Rev. 76(2):45–53.Google Scholar
• Shibayama S, Tanikawa K, Fujimoto R, Kimura H (2008) Effects of mergers and acquisitions on drug discovery: Perspective from a case study of a Japanese pharmaceutical company. Drug Discovery Today 13(1–2):86–93.Crossref, Google Scholar
• Si H, Kavadias S, Loch C (2022) Managing innovation portfolios: From project selection to portfolio design. Production Oper. Management 31(12):4572–4588.Crossref, Google Scholar
• Taneri N, Crama P (2021) Turning the tables in research and development licensing contracts. Management Sci. 67(9):5838–5856.Link, Google Scholar
• Van Nieuwerburgh S, Veldkamp L (2010) Information acquisition and under-diversification. Rev. Econom. Stud. 77(2):779–805.Crossref, Google Scholar
• West J, Bogers M (2014) Leveraging external sources of innovation: A review of research on open innovation. J. Production Innovative Management 31(4):814–831.Crossref, Google Scholar
• Wheelwright S, Clark K (1992) Revolutionizing Product Development: Quantum Leaps in Speed, Efficiency, and Quality (Simon and Schuster, New York).Google Scholar
• Zschoke M, Mantin B, Jewkes E (2014) The effect of competition on R&D portfolio investments. Production Oper. Management 23(8):1439–1449.Crossref, Google Scholar